Literature DB >> 20355165

Temporal indication of cannabis use by means of THC glucuronide determination.

Ute Mareck1, Nadine Haenelt, Hans Geyer, Sven Guddat, Matthias Kamber, Rudolf Brenneisen, Mario Thevis, Wilhelm Schänzer.   

Abstract

According to the regulations of the World Anti-Doping Agency (WADA), the use of cannabinoids is forbidden in competition. In doping controls, the detection of cannabinoid misuse is based on the analysis of the non-psychoactive metabolite 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (carboxy-THC). The determination of values greater than 15 ng/mL in urine represents an adverse analytical finding; however, no accurate prediction of the time of application is possible as the half-life of carboxy-THC ranges between three and four days. Consequently the detection of carboxy-THC in doping control urine samples collected in competition might also result from cannabis use in out-of-competition periods. The analysis of the glucuronide of the pharmacologically active delta 9-tetrahydrocannabinol (THC-gluc) may represent a complementary indicator for the detection of cannabis misuse in competition.An assay for the determination of THC-gluc in human urine was established. The sample preparation consisted of liquid-liquid extraction of urine specimens, and extracts were analysed by liquid chromatography/tandem mass spectrometry (LC-MS/MS). Authentic doping-control urine samples as well as specimens obtained from a controlled smoking study were analysed and assay characteristics such as specificity, detection limit (0.1 ng/mL), precision (>90%), recovery ( approximately 80%), and extraction efficiency (90%) were determined. Copyright (c) 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20355165     DOI: 10.1002/dta.106

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  7 in total

1.  Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.

Authors:  David M Schwope; Erin L Karschner; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2011-08-11       Impact factor: 8.327

2.  Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry.

Authors:  Karl B Scheidweiler; Nathalie A Desrosiers; Marilyn A Huestis
Journal:  Clin Chim Acta       Date:  2012-07-06       Impact factor: 3.786

3.  Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry.

Authors:  David M Schwope; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2011-07-05       Impact factor: 4.142

4.  In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis.

Authors:  Nathalie A Desrosiers; Dayong Lee; Karl B Scheidweiler; Marta Concheiro-Guisan; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-12-01       Impact factor: 4.142

5.  Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis.

Authors:  David M Schwope; Wendy M Bosker; Johannes G Ramaekers; David A Gorelick; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2012-05-15       Impact factor: 3.367

6.  In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis.

Authors:  Karl B Scheidweiler; David M Schwope; Erin L Karschner; Nathalie A Desrosiers; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2013-03-21       Impact factor: 8.327

Review 7.  [Testing for cannabis and synthetic cannabinoids in human specimens].

Authors:  Pascal Kintz
Journal:  Bull Acad Natl Med       Date:  2020-04-16       Impact factor: 0.144

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.